查看文章

Background: Acute myeloid leukemia (AML) is a heterogeneous disease characterized by abnormal clonal expansion and is the most common form of adult acute leukemia. Though hematopoietic stem cell transplant is the standard of care for high-risk AML patients, relapse post-transplantation occurs in 40% of these patients, highlighting the need for new therapeutic approaches such as immunotherapy.

Flow cytometric profiling of 26 AML patient samples demonstrated that CD33 is expressed on> 94% of blasts/LSCs (leukemic stem cells) while CLL-1 is expressed on> 85% of blasts/LSCs at density levels targetable by immunotherapies (1283-2260 molecules per blast), suggesting that immuno-targeting both CD33 and CLL-1 can address AML heterogeneity and reduce chances of tumor resistance. Targeting these antigens, however, can lead to cytopenia due to shared expression on normal hematopoietic cells …